Literature DB >> 15161706

Determination of molecular marker expression can predict clinical outcome in colon carcinomas.

Gennaro Galizia1, Eva Lieto, Francesca Ferraraccio, Michele Orditura, Ferdinando De Vita, Paolo Castellano, Vincenzo Imperatore, Ciro Romano, Fortunato Ciardiello, Bruno Agostini, Carlo Pignatelli.   

Abstract

PURPOSE: Conventional staging procedures are often unable to precisely predict prognosis in colorectal cancer (CRC). In this study, we set out to investigate the possible role of molecular/structural indicators involved in cell cycle regulation (p27 and p53), apoptosis (p53 and p27), and tumor neoangiogenesis [p53, vascular endothelial growth factor (VEGF), and microvessel count] in predicting tumor behavior and clinical outcome in CRC patients EXPERIMENTAL
DESIGN: Analysis of the above indicators was performed by immunohistochemistry on 104 CRC patient samples and 25 normal colon mucosa specimens.
RESULTS: Intense p27 nuclear staining was found in normal colon mucosa, with p53 nuclear staining and VEGF cytoplasmic accumulation <10%, and low microvessel count. In contrast, in CRC samples, p27 was down-regulated in 53.8%, p53 protein was overexpressed in 52%, and VEGF stained positive in 67.3% of the cases, respectively. Multiple regression analysis showed that molecular markers were strongly correlated. In patients treated with curative surgery, a significant relationship was seen between p27 down-regulation and Dukes' stage, nodal status, and the presence of distant metastases. VEGF overexpression correlated significantly with Dukes' stage, tumor (t) and metastasis (m) parameters, and left site. Stepwise regression selected p27, p53, VEGF, and Dukes' stage as the best combination of variables capable of predicting both disease-specific and disease-free survival.
CONCLUSIONS: The investigated indicators may be useful for the prediction of outcome and recurrence rate in curatively treated CRC patients. In conjunction with clinical and pathological staging, they may provide a stronger indication of clinical outcome than staging alone and help better select therapeutic options in CRC patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161706     DOI: 10.1158/1078-0432.CCR-0960-03

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  28 in total

1.  Expression of vascular endothelial growth factor can predict distant metastasis and disease-free survival for clinical stage III rectal cancer following 30-Gy/10-f preoperative radiotherapy.

Authors:  Yifan Peng; Lin Wang; Changzheng Du; Jin Gu
Journal:  Int J Colorectal Dis       Date:  2012-05-30       Impact factor: 2.571

2.  In vivo, dual-modality OCT/LIF imaging using a novel VEGF receptor-targeted NIR fluorescent probe in the AOM-treated mouse model.

Authors:  Amy M Winkler; Photini F S Rice; Jan Weichsel; Jennifer M Watson; Marina V Backer; Joseph M Backer; Jennifer K Barton
Journal:  Mol Imaging Biol       Date:  2011-12       Impact factor: 3.488

3.  Phospho-STAT5 expression is associated with poor prognosis of human colonic adenocarcinoma.

Authors:  Yin-Ling Mao; Zhi-Wei Li; Chang-Jie Lou; Da Pang; Yan-Qiao Zhang
Journal:  Pathol Oncol Res       Date:  2011-01-14       Impact factor: 3.201

4.  Cytoplasmic expression of p27(kip1) is associated with a favourable prognosis in colorectal cancer patients.

Authors:  Nicholas F S Watson; Lindy G Durrant; John H Scholefield; Zahra Madjd; Duncan Scrimgeour; Ian Spendlove; Ian O Ellis; Poulam M Patel
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

5.  Differential expression of angiogenic factors in peripheral nerve sheath tumors.

Authors:  Junji Wasa; Yoshihiro Nishida; Yoshitaka Suzuki; Satoshi Tsukushi; Yoji Shido; Kozo Hosono; Yoshie Shimoyama; Shigeo Nakamura; Naoki Ishiguro
Journal:  Clin Exp Metastasis       Date:  2008-08-05       Impact factor: 5.150

6.  The lymph node ratio is a powerful prognostic factor of node-positive colon cancers undergoing potentially curative surgery.

Authors:  Gennaro Galizia; Michele Orditura; Francesca Ferraraccio; Paolo Castellano; Margherita Pinto; Anna Zamboli; Sabrina Cecere; Ferdinando De Vita; Carlo Pignatelli; Eva Lieto
Journal:  World J Surg       Date:  2009-12       Impact factor: 3.352

7.  Predictive value of vascular endothelial growth factor overexpression in early relapse of colorectal cancer patients after curative resection.

Authors:  Hsiang-Lin Tsai; I-Ping Yang; Chih-Hung Lin; Chee-Yin Chai; Yu-Ho Huang; Chin-Fan Chen; Ming-Feng Hou; Chao-Hung Kuo; Suh-Hang Juo; Jaw-Yuan Wang
Journal:  Int J Colorectal Dis       Date:  2012-09-09       Impact factor: 2.571

8.  Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6.

Authors:  Yoshiko Aoyagi; Hisae Iinuma; Atsushi Horiuchi; Ryu Shimada; Toshiaki Watanabe
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

9.  Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation.

Authors:  Linda Heijmen; Edwin E G W Ter Voert; Iris D Nagtegaal; Paul Span; Johan Bussink; Cornelis J A Punt; Johannes H W de Wilt; Fred C G J Sweep; Arend Heerschap; Hanneke W M van Laarhoven
Journal:  Eur Radiol       Date:  2012-09-23       Impact factor: 5.315

Review 10.  Metastatic colorectal cancer: current systemic treatment options.

Authors:  Ruth E Board; Juan W Valle
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.